We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

This study has been terminated.
(during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00647972
First Posted: April 1, 2008
Last Update Posted: November 23, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mylan Pharmaceuticals
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: No date given
  Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)